Health and Healthcare

Regenerative Medicine Company on Track for IPO This Week

biotech
Thinkstock
The week after the Thanksgiving holiday stacks up to be another quiet one on the initial public offering (IPO) front. In fact, from now until mid-to-late January we are not likely to see a lot of IPO action in the United States. But there is still a little.

No IPOs made an entrance in the short holiday week. IPO ETF manager Renaissance Capital reported that 261 IPOs have priced in the United States so far this year, up about 25% from a year ago. Total proceeds raised come to $82 billion, up more than 66% from 2013. The 2013 IPO total came in at $54.9 billion, the highest total in the past 10 years.

There is just one IPO on the schedule for the week of December 1. Histogenics Corp. is a regenerative medicine company that is developing and commercializing products in the musculoskeletal market. The company plans to offer 4.3 million shares in an IPO price range of $13 to $15, raising $60 million at a market cap of about $151 million. Joint bookrunners for the offering are Cowen, Needham and Canaccord Genuity. Co-manager is BTIG. The stock is expected to price on Tuesday and begin trading Wednesday on the Nasdaq under the ticker symbol HSGX.

As of Sunday there is just one IPO scheduled for the week of December 8 as well. We’ll have more on that one, a REIT that focuses on the Nordic countries, and any others that pop up in our next report.

ALSO READ: 5 Health Care Stocks That Need to Play Serious Catch Up

Credit card companies are handing out rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.